| MEMORIAL SLOAN-KETTERING CANCER CENTER Patent applications |
| Patent application number | Title | Published |
|---|
| 20220296177 | METHODS AND SYSTEMS FOR RETROSPECTIVE INTERNAL GATING - The present invention, in one form, is a method for deriving respiratory gated PET image reconstruction from raw PET data. In reconstructing the respiratory gated images in accordance with the present invention, respiratory motion information derived from individual voxel signal fluctuations, is used in combination to create usable respiratory phase information. Employing this method allows the respiratory gated PET images to be reconstructed from PET data without the use of external hardware, and in a fully automated manner. | 09-22-2022 |
| 20220280488 | PHARMACEUTICALLY ACTIVE PYRAZOLO-PYRIDONE MODULATORS OF DCN1/2-MEDIATED CULLIN NEDDYLATION - A DCN1/2-mediated cullin neddylation modulator; a method for treating disorders associated with dysfunctional DCN1 and/or UBC12, Alzheimer's disease, other neurodegenerative diseases, bacterial infections, or viral infections; and a method for treating cancers are provided. The DCN1/2-mediated cullin neddylation modulator includes a compound according to Formula I disclosed herein. The methods include administering to a mammal a therapeutically effective amount of a compound according to Formula I. Also provided herein is a pharmaceutical composition including a therapeutically effective amount of a compound according to Formula I, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. | 09-08-2022 |
| 20220280424 | METHOD AND COMPOSITION FOR TARGETED DELIVERY OF THERAPEUTIC AGENTS - Pharmaceutical compositions for preventing or reducing kidney injury are disclosed, where the pharmaceutical compositions include (1) siRNAs non-covalently conjugated to functionalized single walled carbon nanotubes (f-SWCNTs) and (2) a pharmaceutically acceptable carrier, where the siRNAs inhibit expression of one or more genes selected from the group consisting of MEP1B and p53 genes. | 09-08-2022 |
| 20220275363 | METHODS FOR IDENTIFYING GENOMIC SAFE HARBORS - The present disclosure provides methods for identifying genomic safe harbors in a genome (e.g., a human genome). | 09-01-2022 |
| 20220267420 | FOXP3 TARGETING AGENT COMPOSITIONS AND METHODS OF USE FOR ADOPTIVE CELL THERAPY - Provided herein are compositions, kits, and methods for manufacturing cells for adoptive cell therapy comprising (a) an engineered receptor, vector encoding an engineered receptor, or engineered immune cell expressing such engineered receptor or comprising such vector; and (b) a Fox P3 targeting agent. | 08-25-2022 |
| 20220259307 | CD33 ANTIBODIES AND METHODS OF USING THE SAME TO TREAT CANCER - The present disclosure relates generally to immunoglobulin-related compositions (e.g., antibodies or antigen binding fragments thereof) that can bind to the CDS 3 protein. The antibodies of the present technology are useful in methods for detecting and treating Alzheimer's disease or a CDS 3-associated cancer in a subject in need thereof. | 08-18-2022 |
| 20220257601 | INHIBITORS OF PRC1 FOR TREATMENT OF CANCER - Disclosed herein are compounds and methods for the inhibition of the RNF1 or RNF2 subunit of polycomb repressive complex 1 (PRC1) for the treatment of metastatic cancer, such as metastatic castration-resistant prostate cancer. The inhibitors can be combined with checkpoint inhibitors such as PD-1 inhibitors, PD-L 1 inhibitors, or CTLA-4 inhibitors. | 08-18-2022 |
| 20220249484 | METHODS FOR PREDICTING RESPONSIVENESS OF CANCER TO FERROPTOSIS-INDUCING THERAPIES - The present disclosure relates generally to methods for determining whether a patient diagnosed with cancer will benefit from or is predicted to be responsive to treatment with a ferroptosis-inducing therapy. These methods are based on screening a cancer patient for mutations in cadherin and/or the Merlin-Hippo-YAP signaling pathway. | 08-11-2022 |
| 20220242967 | ANTI-GLYPICAN-3 ANTIBODIES AND USES THEREOF - The present disclosure relates generally to immunoglobulin-related compositions (e.g., antibodies or antigen binding fragments thereof) that can bind to the Glypican-3 (GPC3) protein. The antibodies of the present technology are useful in methods for detecting and treating GPC3-associated cancers in a subject in need thereof. | 08-04-2022 |
| 20220235143 | HUMANIZED ANTIBODIES TO MUCIN-16 AND METHODS OF USE THEREOF - Provided herein are compositions, methods, and uses involving anti-Mucin-16 (MUC16) agents that immunospecifically bind an epitope of Mucin-16 (MUC16). Also provided herein are uses and methods for managing, treating, or preventing disorders, such as cancer and diseases associated with positive MUC16 expression. | 07-28-2022 |
| 20220235088 | INHIBITORS OF ADENYLATE-FORMING ENZYME MENE - Provided herein are compounds of Formula (I) and pharmaceutically acceptable salts or tautomers thereof which may inhibit adenylate-forming enzymes. Also provided are pharmaceutical compositions, kits, uses, and methods involving the inventive compounds for the treatment and/or prevention of an infectious disease (e.g., bacterial infection (e.g., tuberculosis, methicillin-resistant | 07-28-2022 |
| 20220228123 | METHODS OF DIFFERENTIATING STEM CELL-DERIVED ECTODERMAL LINEAGE PRECURSORS - The presently disclosed subject matter provides for in vitro methods of inducing differentiation of human stem cells into neural crest, cranial placode or non-neuro ectoderm precursors, and cells generated by such methods. The presently disclosed subject matter also provides for uses of such cells for treating neurodegenerative and pituitary disorders. | 07-21-2022 |
| 20220218748 | CELLS FOR IMPROVED IMMUNOTHERAPY AND USES THEREOF - The presently disclosed subject matter provides cells and compositions for improved immunotherapy and methods of using such cells and compositions. It relates to cells comprising a ligand-recognizing receptor (e.g., an antigen-recognizing receptor, e.g., a chimeric antigen receptor (CAR) or a T-cell Receptor (TCR)) and an IgG-degrading enzyme or a fragment thereof. The IgG-degrading enzyme rapidly cleaves IgG. The IgG-degrading enzyme serves as a biomolecular shield against the host humoral response. The cells have increased resistance to host humoral response (e.g., an antibody-driven host humoral response), which allows for prolonged persistence of the cells, leading to enhanced activity of the cells. | 07-14-2022 |
| 20220213211 | ANTIGEN RECOGNIZING RECEPTORS TARGETING CD371 AND USES THEREOF - The presently disclosed subject matter provides for antigen-recognizing receptors that specifically target CD371 and cells comprising such CD371-targeted antigen-recognizing receptors. The presently disclosed subject matter further provides uses of the CD371-targeted antigen-recognizing receptors for treatment. | 07-07-2022 |
| 20220211785 | USE OF MVA OR MVADELTAE3L AS IMMUNOTHERAPEUTIC AGENTS AGAINST SOLID TUMORS - The present disclosure relates to modified vaccinia Ankara (MVA) virus or MVAΔE3L delivered intratumorally or systemically as an anticancer immunotherapeutic agent, alone, or in combination with one or more immune checkpoint blocking agents for the treatment of malignant solid tumors. Particular embodiments relate to mobilizing the host's immune system to mount an immune response against the tumor. | 07-07-2022 |
| 20220211761 | GENOMIC SAFE HARBORS FOR TRANSGENE INTEGRATION - The present disclosure provides genomic safe harbors (GSHs) at which transgenes can be integrated for stable and reliable expression, without disrupting the expression or regulation of the endogenous genes. The present disclosure further provides genetically modified cells comprising a transgene that is integrated within the GSHs disclosed herein. The present disclosure further provides compositions, kits, and formulations comprising genetically modified cells disclosed herein. | 07-07-2022 |
| 20220203132 | MAGNETIC RESONANCE SIGNATURE MATCHING (MRSIGMA) FOR REAL-TIME VOLUMETRIC MOTION TRACKING AND ADAPTIVE RADIOTHERAPY - Described is an approach for tracking 3D organ motion in real-time using magnetic resonance imaging (MRI). The approach may include offline learning, which may acquire signature and 3D imaging data over multiple respiratory cycles to create a database of high-resolution 3D motion states. The approach may further include online matching, which may acquire signature data only in real-time (latency less than 0.2 seconds). From a motion state and motion signature database, the 3D motion state whose signature best (or sufficiently) matches the newly-acquired signature data may be selected. Real-time 3D motion tracking may be accomplished by performing time-consuming acquisition and reconstruction work in an offline learning phase, leaving just signature acquisition and correlation analysis in an online matching step, minimizing or otherwise reducing latency. The approach may be used to adapt radiotherapy procedures based on tumor motion using a magnetic resonance linear accelerator (MR-Linac) system. | 06-30-2022 |
| 20220098329 | HETERODIMERIC TETRAVALENCY AND SPECIFICITY ANTIBODY COMPOSITIONS AND USES THEREOF - The present disclosure relates generally to immunoglobulin-related compositions (e.g., heterodimeric trivalent/tetravalent multispecific antibodies) that specifically bind to three or four distinct target antigens. The immunoglobulin-related compositions described herein are useful in methods for detecting and treating cancer in a subject in need thereof. | 03-31-2022 |
| 20220096567 | METHODS AND COMPOSITIONS FOR REDUCING VANCOMYCIN-RESISTANT ENTEROCOCCI INFECTION OR COLONIZATION - The present invention relates to methods and compositions for reducing the risk and severity of vancomycin-resistant Enterococci infection or colonization. It is based, at least in part, on the discovery that a restricted fraction of the gut microbiota, including the bacteria | 03-31-2022 |
| 20220074945 | CANCER ANTIGEN TARGETS AND USES THEREOF - The presently disclosed subject matter provides methods and compositions for treating myeloid disorders (e.g., acute myeloid leukemia (AML)). It relates to immunoresponsive cells bearing antigen recognizing receptors (e.g., chimeric antigen receptors (CARs)) targeting AML-specific antigens. | 03-10-2022 |
| 20210406611 | MULTI-TASK LEARNING FOR DENSE OBJECT DETECTION - Presented herein are systems and methods for feature detection in images. A computing system may identify a biomedical image having features. The computing system may apply the biomedical image to a feature detection model. The feature detection model may include an encoder-decoder block to generate a feature map corresponding to the biomedical image, a confidence map generator having a second set of parameters to generate a confidence map using the feature map, and a localization map generator to generate a localization map using the feature map. The computing system may generate a resultant map based on the confidence map and the localization map. The resultant map identifying one or more points corresponding to the one or more features. The computing system may provide the one or more points identified in the resultant map for the biomedical image. | 12-30-2021 |
| 20210403597 | ANTIBODIES TO MUCIN-16 AND METHODS OF USE THEREOF - Provided herein are compositions, methods, and uses involving anti-Mucin-16 (MUC16) agents that immunospecifically bind an epitope of Mucin-16 (MUC16). Also provided herein are uses and methods for managing, treating, or preventing disorders, such as cancer and diseases associated with positive MUC16 expression. | 12-30-2021 |
| 20210393690 | METHODS FOR TREATMENT USING CHIMERIC ANTIGEN RECEPTORS SPECIFIC FOR B-CELL MATURATION ANTIGEN - Provided herein are adoptive cell therapy methods involving the administration of doses of cells for treating disease and conditions, including certain plasma cell malignancy. The cells generally express recombinant receptors such as chimeric antigen receptors (CARs) specific to B-cell maturation antigen (BCMA). In some embodiments, the methods are for treating subjects with multiple myeloma (MM). Also provided are genetically engineered cells containing such BCMA-binding receptors for uses in adoptive cell therapy. | 12-23-2021 |
| 20210393689 | CHIMERIC ANTIGEN RECEPTORS SPECIFIC FOR G PROTEIN-COUPLED RECEPTOR CLASS C GROUP 5 MEMBER D (GPRC5D) - Provided are chimeric antigen receptors (CARs), which contain antibody portions specific to G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D) and polynucleotides that encode CARs specific for GPRC5D. The disclosure further relates to genetically engineered cells, containing such GPRCSD-binding receptors, and uses thereof in adoptive cell therapy. | 12-23-2021 |
| 20210388081 | ANTIBODIES TARGETING FC RECEPTOR-LIKE 5 AND METHODS OF USE - The presently disclosed subject matter provides fully human antibodies or antigen-binding fragments thereof that bind to FcRL5 and methods of using the same. | 12-16-2021 |
| 20210379046 | Methods of Treating Diseases Using Kinase Modulators - Provided herein are methods of modulating immune response, including methods of treating a cancer or an infection using a combination of kinase modulators and immunotherapy that promotes immune response. Also provided herein are methods of treating an autoimmune disease or graft-versus-host disease, and methods of reducing the risk of solid organ transplant rejection using a combination of kinase modulators and immunosuppressive therapy. | 12-09-2021 |
| 20210369795 | METHODS AND COMPOSITIONS FOR IDENTIFYING AND TREATING SUBJECTS AT RISK FOR CHECKPOINT BLOCKADE THERAPY ASSOCIATED COLITIS - The present invention relates to methods and compositions for identifying subjects treated with or considered for treatment with checkpoint blockade therapeutic agents that are at higher or lower risk for developing checkpoint therapy associated colitis, by analyzing the intestinal microbiome of those subjects. It is based, at least in part, on the discovery that the abundance of certain intestinal microbiota of the phyla Bacteroidetes, including the bacteria in the families Bacteroidaceae, Rikenellaceae, and Barnesisllaceae, and/or an increase or decrease in microbial genetic pathways involved in polyamine transport and/or B vitamin biosynthesis (e.g., (riboflavin (B2), pantothenate (B5) and thiamine (B1)) are associated with the likelihood of developing checkpoint therapy associated colitis. | 12-02-2021 |
| 20210369781 | COMPOSITIONS AND METHODS FOR IMMUNOTHERAPY - The present invention provides for methods and compositions for enhancing the immune response toward cancers and pathogens. It relates to immunoresponsive cells bearing antigen receptors, which can be chimeric antigen receptors (CARs), which express introduced ligands for immunomodulatory molecules. In particular embodiments, engineered immunoresponsive cells are antigen-directed and resist immunosuppression and/or have enhances immune-activating properties. | 12-02-2021 |
| 20210346432 | METHODS OF USING CHIMERIC ANTIGEN RECEPTORS TARGETING B-CELL MATURATION ANTIGEN AND USES THEREOF - The presently disclosed subject matter provides for methods and compositions for treating multiple myeloma. It relates to chimeric antigen receptors (CARs) that specifically target B cell maturation antigen (BCMA), and immunoresponsive cells comprising such CARs. The presently disclosed BCMA-specific CARs have enhanced immune-activating properties, including anti-tumor activity. | 11-11-2021 |
| 20210346354 | MACROPINOCYTOSIS IN CANCER - Disclosed herein are compositions and methods for detecting and treating cancer. In some embodiments, the cancer is characterized by activation of Ras. | 11-11-2021 |
| 20210332436 | STEM CELL-BASED MULTIPLEX METHODS AND COMPOSITIONS - The present disclosure relates to pluripotent stem cell (e.g., human PSC) based multiplex methods and compositions for identifying genes associated with the pathogenesis of a disorder (e.g., human disorder) and the responsiveness to certain treatments to such disorder. The present disclosure also provides genetic markers for identifying clinically relevant subpopulations of autism patients. | 10-28-2021 |
| 20210324100 | CHIMERIC ANTIGEN RECEPTORS SPECIFIC FOR B-CELL MATURATION ANTIGEN AND ENCODING POLYNUCLEOTIDES - Provided herein are chimeric receptors, such as chimeric antigen receptors (CARs), comprising BCMA-binding molecules, such as anti-BCMA antibodies and antigen-binding fragments thereof, such as heavy chain variable (V | 10-21-2021 |
| 20210315868 | KINASE MUTATION-ASSOCIATED NEURODEGENERATIVE DISORDERS - The present technology relates to methods for treating, preventing, and/or ameliorating kinase mutation-associated neurodegenerative diseases, including BRAFV600E-associated neurodegenerative diseases, in a subject in need thereof. In particular aspects, the present technology relates to the use of BRAF, MEK, and/or CSF-IR inhibitors to treat, prevent, and/or ameliorate kinase mutation-associated neurodegenerative diseases, including BRAFV600E-associated neurodegenerative diseases. | 10-14-2021 |
| 20210309758 | ANTIBODIES TO MUC16 AND METHODS OF USE THEREOF - The invention provides antibodies, and antigen-binding fragments thereof, that specifically bind to a polypeptide, or antigenic portion thereof, wherein the polypeptide is selected from a) MUC16 ectodomain polypeptide, b) MUC16 cytoplasmic domain polypeptide, and c) MUC16 extracellular domain polypeptide that contains a cysteine loop polypeptide. The invention's antibodies and compositions containing them are useful in diagnostic and therapeutic applications for diseases in which MUC16 is overexpressed, such as cancer. | 10-07-2021 |
| 20210198379 | METHODS FOR TREATING NEUROBLASTOMA WITH COMBINATION THERAPY - The present disclosure provides methods of treating neuroblastoma using an anti-GD2 antibody, at least one chemotherapeutic agent, and at least one hematopoietic growth factor. The present disclosure also provides compositions for treating neuroblastoma. | 07-01-2021 |
| 20210179686 | CELL SORTING SYSTEMS AND METHODS OF USE - The presently disclosed subject matter provides methods and systems for isolating cells expressing specific constructs. In certain non-limiting embodiments, the system comprises a membrane-bound polypeptide and a soluble polypeptide that is capable of dimerizing with the membrane-bound polypeptide. | 06-17-2021 |
| 20210177964 | HEAT-INACTIVATED VACCINIA VIRUS AS A VACCINE IMMUNE ADJUVANT - The technology of the present disclosure relates to the use of Heat-inactivated modified vaccinia Ankara (MVA) vims (Heat-iMVA) or Heat-inactivated vaccinia vims as a vaccine immune adjuvant. In particular, the present technology relates to the use of Heat-iMVA as a vaccine adjuvant for tumor antigens in cancer vaccines alone or in combination with immune checkpoint blockade (ICB) antibodies for use as a cancer immunotherapeutic. | 06-17-2021 |
| 20210032350 | ANTIBODIES TO GALECTIN-3 AND METHODS OF USE THEREOF - Provided herein are compositions, methods, and uses involving antibodies that immunospecifically bind the Galactin-3 (LGALS3) carbohydrate binding domain (CBD). Also provided herein are uses and methods for managing, treating, or preventing disorders, such as cancer. | 02-04-2021 |
| 20210030804 | CELLS COMPRISING NON-HLA RESTRICTED T CELL RECEPTORS - The presently disclosed subject matter provides methods and compositions for enhancing the immune response toward cancers and pathogens. It relates to novel designs of T cell receptors (TCRs) and engineered immunoresponsive cells comprising the same. The novel TCR binds to an antigen in an HLA-independent manner. In certain embodiments, the novel TCR provides enhanced sensitivity for a target gene having a low expression level. | 02-04-2021 |
| 20200407680 | MIDBRAIN DOPAMINE (DA) NEURONS FOR ENGRAFTMENT - The present invention relates to the field of stem cell biology, in particular the lineage specific differentiation of pluripotent or multipotent stem cells, which can include, but is not limited to, human embryonic stem cells (hESC) in addition to nonembryonic human induced pluripotent stem cells (hiPSC), somatic stem cells, stem cells from patients with a disease, or any other cell capable of lineage specific differentiation. Specifically described are methods to direct the lineage specific differentiation of hESC and/or hiPSC into floor plate midbrain progenitor cells and then further into large populations of midbrain fate FOXA2 | 12-31-2020 |
| 20200292640 | HYPERPOLARIZED MICRO-NMR SYSTEM AND METHODS - Described herein are micro-coil hyperpolarized NMR systems and methods for measuring metabolic flux in living and non-living samples. Such systems can perform high throughput measurements (with multiple coils) of metabolic flux without destroying the material, making it useful to analyze tumor biopsies, cancer stem cells, and the like. In certain embodiments, a hyperpolarized micromagnetic resonance spectrometer (HMRS), described herein, is used to achieve real-time, significantly more sensitive (e.g., 10 | 09-17-2020 |
| 20200291433 | GLOBIN GENE THERAPY FOR TREATING HEMOGLOBINOPATHIES - The presently disclosed subject matter provides for expression cassettes that allow for expression of a globin gene or a functional portion thereof, vectors comprising thereof, and cells transduced with such expression cassettes and vectors. The presently disclosed subject matter further provides methods for treating a hemoglobinopathy in a subject comprising administering an effective amount of such transduced cells to the subject. | 09-17-2020 |
| 20200291112 | A33 ANTIBODY COMPOSITIONS AND METHODS OF USING THE SAME IN RADIOIMMUNOTHERAPY - The present disclosure relates generally to immunoglobulin-related compositions (e.g., antibodies or antigen binding fragments thereof) that can bind to and neutralize the activity of A33 protein. The antibodies of the present technology are useful in methods for detecting and treating an A33-positive cancer in a subject in need thereof. | 09-17-2020 |
| 20200260983 | HYPERPOLARIZED AND DEUTERIUM EXCHANGED HYPERPOLARIZED13C AND 15N-LABELED XANTHINE, ARGININE, GLUTAMINE, AND UREA PROBES - The present technology provides | 08-20-2020 |
| 20200085886 | METHODS AND COMPOSITIONS FOR REDUCING LISTERIA MONOCYTOGENES INFECTION OR COLONIZATION - The disclosure relates to a therapeutic composition for treating | 03-19-2020 |
| 20200085781 | METHODS FOR TREATING BRAIN METASTASIS - The present invention relates to methods for treating brain metastasis by inhibiting gap junction functionality. It is based, at least in part, on the discovery that cancer cells expressing Protocadherin 7 and Connexin 43 form gap junctions with astrocytes that promote the growth of brain metastases, and that inhibition of Protocadherin 7 and/or Connexin 43 expression in cancer cells reduce progression of brain metastases. It is further based on the discovery that treatment with gap junction inhibitors tonabersat and meclofenamate inhibited progression of brain metastatic lesions and enhanced the anti-cancer activity of the conventional chemotherapeutic agent, carboplatin. | 03-19-2020 |
| 20190314642 | INTERNAL BODY CAVITY THERAPEUTIC APPLICATOR ARRANGEMENTS AND METHODS FOR USING THE SAME | 10-17-2019 |
| 20190276509 | AGENTS AND METHODS FOR TREATING CBP-DEPENDENT CANCERS | 09-12-2019 |
| 20190276488 | ADENOSINE ANALOGS AS METHYLTRANSFERASE INHIBITORS FOR TREATING CANCER | 09-12-2019 |
| 20190275179 | SONOPHORE-LABELED PROBES AND RELATED IN VIVO IMAGING TECHNIQUES | 09-12-2019 |
| 20190270997 | INHIBITION OF KMT2D FOR THE TREATMENT OF CANCER - The presently disclosed subject matter relates to the administration of a KMT2D inhibitor for the treatment of a cancer. The present invention is based on the discovery that upon PI3K inhibition, KMT2D activity is upregulated, resulting in an increase in the expression of genes involved in breast cancer cell proliferation and tumor growth. Accordingly, the present invention provides methods for treating a subject that has cancer by administering a therapeutically effective amount of an KMT2D inhibitor. | 09-05-2019 |
| 20190270776 | IMMUNOGENIC WT-1 PEPTIDES AND METHODS OF USE THEREOF - This invention provides peptides, immunogenic compositions and vaccines comprising same, and methods of treating, reducing the incidence of, and inducing immune responses to a WT1-expressing cancer, comprising same. | 09-05-2019 |
| 20190002463 | ANTI-PARASITIC COMPOUNDS AND USES THEREOF - The present disclosure provides compounds of Formula (I′), Formula (II), and Formula (III). The compounds described herein may useful in treating and/or preventing protozoan infections in a subject in need thereof, treating and/or preventing trypanosomal infections (e.g., | 01-03-2019 |
| 20190000881 | CONSTITUTIVE EXPRESSION OF COSTIMULATORY LIGANDS ON ADOPTIVELY TRANSFERRED T LYMPHOCYTES - The present invention provides immunoresponsive cells, including T cells, cytotoxic T cells, regulatory T cells, and Natural Killer (NK) cells, expressing at least one of an antigen-recognizing receptor and a co-stimulatory ligand and methods of use therefore for the treatment of neoplasia and other pathologies where an increase in an antigen-specific immune response is desired. | 01-03-2019 |
| 20180371085 | ANTIBODIES TARGETING FC RECEPTOR-LIKE 5 AND METHODS OF USE - The presently disclosed subject matter provides fully human antibodies or antigen-binding fragments thereof that bind to FcRL5 and methods of using the same. | 12-27-2018 |
| 20170258758 | METHODS FOR TREATING BRAIN METASTASIS - The present invention relates to methods for treating brain metastasis by inhibiting gap junction functionality. It is based, at least in part, on the discovery that cancer cells expressing Protocadherin 7 and Connexin 43 form gap junctions with astrocytes that promote the growth of brain metastases, and that inhibition of Protocadherin 7 and/or Connexin 43 expression in cancer cells reduce progression of brain metastases. It is further based on the discovery that treatment with gap junction inhibitors tonabersat and meclofenamate inhibited progression of brain metastatic lesions and enhanced the anti-cancer activity of the conventional chemotherapeutic agent, carboplatin. | 09-14-2017 |
| 20170175164 | L-2-HYDROXYGLUTARATE AND STRESS INDUCED METABOLISM - The present disclosure provides, among other things, methods and compositions for diagnosing and treating stress-induced injuries, hypoxia in particular. The present invention is based, in part, on the novel discovery that a metabolite, L-2-hydroxyglutarate, and certain enzymes and substrates regulating its metabolism, mediate stress-induced cellular mechanisms. In some embodiments, provided methods and compositions are used to diagnose and treat diseases with hypoxia-induced injuries. In some embodiments, provided methods and compositions are used to modulate cell pluripotency or differentiation in vivo or in vitro. | 06-22-2017 |
| 20170173185 | GLOBIN GENE THERAPY FOR TREATING HEMOGLOBINOPATHIES - The presently disclosed subject matter provides for expression cassettes that allow for expression of a globin gene or a functional portion thereof, vectors comprising thereof, and cells transduced with such expression cassettes and vectors. The presently disclosed subject matter further provides methods for treating a hemoglobinopathy in a subject comprising administering an effective amount of such transduced cells to the subject. | 06-22-2017 |
| 20170172477 | HANDHELD APPARATUS TO DETERMINE THE VIABILITY OF A BIOLOGICAL TISSUE - The present invention provides for a handheld apparatus for in vivo examination of the viability of a biological tissue. | 06-22-2017 |
| 20170159012 | Kits For Neural Conversion of Human Embryonic Stem Cells - The present invention relates generally to the field of cell biology of stem cells, more specifically the directed differentiation of pluripotent or multipotent stem cells, including human embryonic stem cells (hESC), somatic stem cells, and induced human pluripotent stem cells (hiPSC) using novel culture conditions. Specifically, methods are provided for obtaining neural tissue, floor plate cells, and placode including induction of neural plate development in hESCs for obtaining midbrain dopamine (DA) neurons, motorneurons, and sensory neurons. Further, neural plate tissue obtained using methods of the present inventions are contemplated for use in co-cultures with other tissues as inducers for shifting differentiation pathways, i.e. patterning. | 06-08-2017 |
| 20170042881 | TREATMENT OF H-RAS-DRIVEN TUMORS | 02-16-2017 |
| 20170022475 | MODULATING CELL PROLIFERATION AND PLURIPOTENCY - Disclosed herein are compositions, systems, and methods for modulating proliferation, differentiation and pluripotency of cells. | 01-26-2017 |
| 20160375060 | Methods of Treating Glioblastoma Multiforme by T Cell Therapy - Disclosed herein are methods of treating glioblastoma multiforme (GBM) in a human patient in need thereof, comprising administering to the human patient a population of allogeneic T cells comprising CMV (cytomegalovirus)-specific T cells. | 12-29-2016 |
| 20160331750 | METHODS FOR TREATMENT OF LYMPHOMAS WITH MUTATIONS IN CELL CYCLE GENES - The present disclosure identifies a novel subtype of follicular lymphoma (FL) characterized by dysregulation of the cyclin/CDK/RB proliferative pathway. This subtype of FL is associated with increased malignancy and mortality, relative to FL which is not associated with cell cycle dysregulation. Accordingly, this disclosure presents novel methods to subtype FL and stratify patient risk by detection of biomarkers associated with RB inactivation. This disclosure further presents novel therapies for the treatment of FL subtyped by inactivation of RB. | 11-17-2016 |
| 20160184433 | CERAMIDE REVERSAL OF MULTI-DRUG RESISTANCE - Based on the observation that the application of small amounts of exogenous acid sphingomyelinase to generate endogenous ceramide, or provision of exogenous long-chain natural C16-ceramide resulted in rapid translocation of vacuolar daunorubicin into the nucleus in multi-drug resistant (MDR) cells, the present invention relates to a nano-liposomal preparation that includes C16-ceramide. Exposure of MDR cells to the C16:0 ceramide-based nanoliposomes provide a mechanism to reverse MDR in chemoresistant cells and tumors, by inducing rapid translocation of chemotherapeutic agent from cytoplasmic vesicles to the nucleus. | 06-30-2016 |
| 20160138115 | METHODS AND CHARACTERISTICS FOR THE DIAGNOSIS OF ACUTE LYMPHOBLASTIC LEUKEMIA - Methods for identification of leukemia or a genetic predisposition to leukemia are provided that are particularly applicable to acute lymphoblastic leukemia (ALL). A novel heterozygous germline variant, c.547G>A (p.Gly183Ser) in the octapeptide domain of PAX5, is used to identify those individuals with an enhanced risk or predisposition to ALL. | 05-19-2016 |
| 20160138021 | COMPOSITIONS AND METHODS FOR TREATING CANCER AND OTHER DISEASES - Aptamers and improved aptamers are provided with enhanced efficacy for binding to target molecules in vivo or for treating cancer or other diseases. Such improvements in aptamers are provided that enhance in vivo efficacy such as binding to the target molecule or enhancing anti-cancer activity. Such improvements also include stability to serum nucleases, reduced binding to a soluble form of the target molecule, increased avidity, affinity or specificity to the target molecule on a cell surface, increased lifetime in circulation, or any combination of the foregoing. Improvements are provided by truncation, multimerization, including at least one non-natural nucleic acid, adding a 3′ or 5′ polyethylene glycol, or any combination thereof. Aptamers for treatment of autoimmune diseases are also provided. | 05-19-2016 |
| 20160136244 | METHODS OF USE FOR IL-22 PROMOTING REJUVENATION OF THYMIC AND BONE MARROW FUNCTION - The present invention provides methods and compositions for the use of IL-22 to promote thymic growth following thymic insult. In particularly preferred embodiments, the present invention provides methods of using therapeutic IL-22 compositions for treating patients with thymic atrophy and alterations in bone marrow derived white blood cells, including cancer patients undergoing chemotherapy, patients exposed to radiation (i.e. cancer therapy, nuclear disaster, terrorist attack, etc.), patients with HIV infections/AIDS, patients with organ transplantation, aging patients, and the like. In a further embodiment, therapeutic IL-22 compositions are contemplated as a prophylactic to boost immune response when additional T-cell function is needed, i.e. to boost immune response during vaccination. | 05-19-2016 |
| 20160136142 | TREATMENT OF PANCREATIC AND RELATED CANCERS WITH 5-ACYL-6,7-DIHYDROTHIENO[3,2-C]PYRIDINES - Methods for inhibiting the growth of pancreatic cancer cells or other cancer cells driven by Sonic hedgehog are disclosed. The method involves exposing the cells to 5-acyl-6,7-dihydrothieno[3,2-c]pyridines of formula I | 05-19-2016 |
| 20160120832 | LIPID SCAVENGING IN RAS CANCERS - Methods and compositions for treating Ras-related cancers are provided that involve targeting lipid scavenging. Methods and compositions for identifying and/or characterizing more or less responsive cancers are also provided. | 05-05-2016 |
| 20160115448 | CORTICAL INTERNEURONS AND OTHER NEURONAL CELLS PRODUCED BY THE DIRECTED DIFFERENTIATION OF PLURIPOTENT AND MULTIPOTENT CELLS - Provided are cortical interneurons and other neuronal cells and in vitro methods for producing such cortical interneurons and other neuronal cells by the directed differentiation of stem cells and neuronal progenitor cells. The present disclosure relates to novel methods of in vitro differentiation of stem cells and neural progenitor cells to produce several type neuronal cells and their precursor cells, including cortical interneurons, hypothalamic neurons and pre-optic cholinergic neurons. The present disclose describes the derivation of these cells via inhibiting SMAD and Wnt signaling pathways and activating SHH signaling pathway. The present disclosure relates to the novel discovery that the timing and duration of SHH activation can be harnessed to direct controlled differentiation of neural progenitor cells into either cortical interneurons, hypothalamic neurons or pre-optic cholinergic neurons. The present disclosure also relates to compositions of cortical interneurons, hypothalamic neurons or pre-optic cholinergic neurons, and their precursors, that are highly enriched and can be used in variety of application. These cells can be used therapeutically to treat neurodegenerative and neuropsychiatric disorders, and can be used for disease modeling and drug screening. | 04-28-2016 |
| 20160115444 | AGE-MODIFIED CELLS AND METHODS FOR MAKING AGE-MODIFIED CELLS - Provided are age-modified cells and method for making age modified cells using progerin or a progerin-like protein. The aging and/or maturation process can be accelerated and controlled for young and/or immature cells, such as a somatic cell, a stem cell, a stem cell-derived somatic cell, including an induced pluripotent stem cell-derived cell, by contacting with progerin or a progerin-like protein. Methods described by the present disclosure can produce age-appropriate cells from a somatic cell or a stem cell, such as an old cell and/or a mature cell. Such age-modified cells constitute model systems for the study of late-onset diseases and/or disorders. | 04-28-2016 |
| 20160109430 | METHODS FOR DRUG DISCOVERY - The present invention provides assays for identifying drug candidates that regulate cellular senescence. In particular, the present invention relates to the use of ATRX foci as a biomarker for determining whether one or more drug candidates regulate senescence in a cell line. In one non-limiting embodiment, the present invention provides assays to identify compounds that can be used in a combinatorial cancer treatment. The present invention is based, at least in part, on the discovery that the number of ATRX foci increases in cells that undergo senescence. Accordingly, in non-limiting embodiments, the present invention provides for assays and kits for identifying drug combinations that may be useful in treating subject that have cancer and for identifying compounds that may be useful in treating age-related diseases. | 04-21-2016 |
| 20160068560 | COMPOSITIONS AND METHODS FOR ALTERING SECOND MESSENGER SIGNALING - The invention relates to compositions, methods, kits, and assays related to the use and/or exploitation of isomers of cGAMP as well as the structure of the enzyme cGAS. | 03-10-2016 |
| 20160045551 | COMPOSITIONS AND METHODS FOR IMMUNOTHERAPY - The present invention provides for methods and compositions for enhancing the immune response toward cancers and pathogens. It relates to immunoresponsive cells bearing antigen receptors, which can be chimeric antigen receptors (CARS), which express introduced ligands for immunomodulatory molecules. In particular embodiments, engineered immunoresponsive cells are antigen-directed and resist immunosuppression and/or have enhances immune-activating properties. | 02-18-2016 |
| 20160030433 | COMPANION DIAGNOSTIC FOR CDK4 INHIBITORS - The present invention relates to the use of one or more biomarkers to evaluate the likelihood that a CDK4 inhibitor would produce an anti-cancer effect in a subject. It is based, at least in part, on the discovery that cancer treatment with a CDK4 inhibitor is more effective where treated cancer cells undergo cellular senescence rather than a transient cell cycle arrest, where cellular senescence is associated with decreased MDM2 protein level. Accordingly, in non-limiting embodiments, the present invention provides for methods, compositions, and kits for a companion diagnostic for CDK4 inhibitors, and in particular, to the use of MDM2 expression as a biomarker for the likelihood that a cancer can be successfully treated by CDK4 inhibition. | 02-04-2016 |
| 20160015760 | NEWCASTLE DISEASE VIRUSES AND USES THEREOF - Described herein are chimeric Newcastle disease viruses engineered to express an agonist of a co-stimulatory signal of an immune cell and compositions comprising such viruses. Also described herein are chimeric Newcastle disease viruses engineered to express an antagonist of an inhibitory signal of an immune cell and compositions comprising such viruses. The chimeric Newcastle disease viruses and compositions are useful in the treatment of cancer. In addition, described herein are methods for treating cancer comprising administering Newcastle disease viruses in combination with an agonist of a co-stimulatory signal of an immune and/or an antagonist of an inhibitory signal of an immune cell. | 01-21-2016 |
| 20150352201 | IMMUNOGENIC WT-1 PEPTIDES AND METHODS OF USE THEREOF - This invention provides peptides, immunogenic compositions and vaccines, and methods of treating, reducing the incidence of, and inducing immune responses to a WT1-expressing cancer, comprising heteroclitic peptides derived from the WT-1 protein. | 12-10-2015 |
| 20150342993 | COMPOSITIONS AND METHODS FOR IMMUNOTHERAPY - The present invention provides immunoresponsive cells, including T cells, cytotoxic T cells, regulatory T cells, and Natural Killer (NK) cells, expressing at least one of an antigen recognizing receptor and one of a chimeric costimulatory receptor. Methods of using the immunoresponsive cell include those for the treatment of neoplasia and other pathologies where an increase in an antigen-specific immune response is desired. | 12-03-2015 |
| 20150291565 | INDOLE COMPOUNDS AND THEIR USE AS ANTIMICROBIALS - Indole compounds of formula I, as well as compositions including the compounds and methods for their use, are disclosed that are useful for treating bacterial and/or fungal infections. Indole compounds of formula I, compositions and methods are disclosed that also are useful for killing or inhibiting the growth of bacteria and/or fungus: | 10-15-2015 |
| 20150268248 | CELL SELECTIVE PROTEOME LABELING - The invention relates to a method for the Cell Type specific labeling with Amino acid Precursors (CTAP). In particular, the disclosed method permits the incorporation of stable isotope-labeled amino acids into the proteome of a vertebrate cell that has been engineered to express an exogenous enzyme that enables the cell to produce an essential amino acid from its amino acid substrate. The method employs stable isotope-labeled amino acid substrate/precursors from which essential amino acids bearing the label are generated. The labeled amino acids generated by the transgenic cell not only supports growth but specifically labels proteins of the transgenic cell. Furthermore, the use of different populations of cells expressing different exogenous amino acid-producing enzymes permits differential labeling of the proteomes of the individual cell populations in multicellular environments. | 09-24-2015 |
| 20150265587 | ANDROGEN RECEPTOR VARIANTS AND METHODS FOR MAKING AND USING - The present invention encompasses the recognition that an F876L mutation of the androgen receptor (AR) gene confers resistance to the antiandrogens enzalutamide (MDV3100) and ARN-509 and is associated with incidence and/or risk of castration resistant prostate cancer (CRPC). The present invention also provides other AR polypeptide sequences associated with increased incidence and/or risk of CRPC. The present invention also provides screening methods for identification and/or characterization of novel AR polypeptide sequences associated with increased incidence and/or risk of CRPC via exposure to antiandrogens and for identification and/or characterization of agents to treat and/or reduce risk of CRPC by virtue of their effect on AR transcriptional activation. | 09-24-2015 |
| 20150259436 | T CELL RECEPTOR-LIKE ANTIBODIES SPECIFIC FOR A WTI PEPTIDE PRESENTED BY HLA-A2 - The present invention provides antigen binding proteins that specifically bind to Wilms' tumor protein (WT1), including humanized, chimeric and fully human antibodies against WT1, antibody fragments, chimeric antigen receptors (CARs), fusion proteins, and conjugates thereof. The antigen binding proteins and antibodies bind to HLA-A0201-restricted WT1 peptide. Such antibodies, fragments, fusion proteins and conjugates thereof are useful for the treatment of WT1 associated cancers, including for example, breast cancer, ovarian cancer, prostate cancer, chronic myelocytic leukemia, multiple myeloma, acute lymphoblastic leukemia (ALL), acute myeloid/myelogenous leukemia (AML) and myelodysplastic syndrome (MDS). In more particular embodiments, the anti-WT1/A antibodies may comprise one or more framework region amino acid substitutions designed to improve protein stability, antibody binding and/or expression levels. | 09-17-2015 |
| 20150240314 | GENES ASSOCIATED WITH DASATINIB SENSITIVITY - The invention relates to a method for the Cell Type specific labeling with Amino acid Precursors (CTAP). In particular, the disclosed method permits the incorporation of stable isotope-labeled amino acids into the proteome of a vertebrate cell that has been engineered to express an exogenous enzyme that enables the cell to produce an essential amino acid from its amino acid substrate. The method employs stable isotope-labeled amino acid substrate/precursors from which essential amino acids bearing the label are generated. The labeled amino acids generated by the transgenic cell not only supports growth but specifically labels proteins of the transgenic cell. Furthermore, the use of different populations of cells expressing different exogenous amino acid-producing enzymes permits differential labeling of the proteomes of the individual cell populations in multicellular environments. | 08-27-2015 |
| 20150219624 | METHODS FOR IDENTIFYING ANTI-CANCER COMPOUNDS - Methods are provided for identifying agents capable of modulating cap-dependent RNA translation by comparing translation efficiency in the presence and absence of the agent in an in-vitro or in-vivo translation system that comprises eIF4A and an mRNA having one or more eIF4A-dependent translation-controlling motifs. The modulation of translation in the presence of the agent indicates the agent as capable of modulating cap-dependent mRNA translation. The method can be used to identify anti-cancer agents and oncogenes that may be responsible for tumorigenesis. | 08-06-2015 |
| 20150191792 | GENE EXPRESSION PROFILE ASSOCIATED WITH PROSTATE CANCER - Using an RT-PCR platform, detection of gene transcripts highly expressed in prostate tissue and expressed in peripheral blood mononuclear cells (PBMC) from patients with mCRPC can provide a more reliable and robust prediction of poor overall survival than that of CTC enumeration in mCRPC. Disclosed is the identification of five genes, KLK3, KLK2, HOXB13, GHRL2 and FOXA1, the detection of two (2) or more transcripts of which predicts overall poor survival. The test is performed on blood samples that have been collected in collection tubes that stabilize intracellular RNA, require minimal on-site processing and can be easily stored and shipped for subsequent extraction of total RNA from whole blood for RT-PCR. | 07-09-2015 |
| 20150185224 | PREDICTING BLADDER CANCER RESPONSIVENESS TO BCG - Calmette-Guerin (BCG) administration plays a central role in managing carcinoma in situ of the bladder. Unfortunately, recurrence or progression of disease is seen in up to 30% of treated patients. Disclosed herein is a method for predicting responsiveness to treatment with BCG based on BCG internalization by bladder cancer cells, the presence or absence of mutations associated with BCG uptake or a combination thereof. | 07-02-2015 |
| 20150184247 | GENE EXPRESSION PROFILES ASSOCIATED WITH METASTATIC BREAST CANCER - A gain-of-function retroviral cDNA screen reveals that Coco, a secreted antagonist of TGF-β ligands, induces solitary mammary carcinoma cells, which have disseminated to others sites and undergone an extended period of dormancy, to exit from dormancy at lung metastatic sites. Evidence indicates that Coco awakens tumor progenitor cells that have extravasated into the lung by inhibiting stroma-derived Bone Morphogenetic Proteins (BMP). Whereas Coco enhances the manifestation of traits associated with cancer stem cells, activation of canonical BMP signaling suppresses these processes. Expression of Coco correlates with lung metastatic capacity in a number of human breast cancer cell lines and induces a gene expression signature that predicts metastatic relapse to the lung but not to the bone in advanced primary tumors. Disclosed herein is the gain-of-function retroviral cDNA screen and a gene signature predictive of selective relapse and gene expression microarrays or panels based thereon for use in prognostication of relapse. | 07-02-2015 |
| 20150104413 | IMMUNOGENIC WT-1 PEPTIDES AND METHODS OF USE THEREOF - This invention provides peptides, immunogenic compositions and vaccines, and methods of treating, reducing the incidence of, and inducing immune responses to a WT-1-expressing cancer, comprising peptides derived from the WT-1 protein. | 04-16-2015 |
| 20150086481 | DIAGNOSIS AND TREATMENT OF PARKINSON'S DISEASE - GUCY2C receptor ligands conjugated to diagnostic and/or therapeutic moieties, methods of making such GUCY2C receptor ligands conjugates, and methods of using such GUCY2C receptor ligands conjugates, such as in the diagnosis and/or treatment of Parkinson's disease, are described. | 03-26-2015 |
| 20150073398 | APPARATUS, SYSTEM AND METHOD FOR PROVIDING LASER STEERING AND FOCUSING FOR INCISION, EXCISION AND ABLATION OF TISSUE IN MINIMALLY-INVASIVE SURGERY - Provided and described herein are exemplary embodiments of apparatus, system, computer-accessible medium, procedure and method according to the present disclosure which can be used for providing laser steering and focusing for, e.g., incision, excision and/or ablation of tissue in minimally-invasive surgery. For example, an exemplary apparatus is provided that can include at least one optical element which can be configured to refract and/or diffract light provided in a structure which can be configured to be inserted into a body, where at least one of the optical element(s) is structured to receive the light at a first angle and generate a refracted and/or diffracted light at a second angle which can be different from the first angle relative to an optical axis. According to a particular exemplary embodiment of the present disclosure, it is possible to control a light propagating arrangement to (i) provide the at least one light toward the optical element(s) at the first angle, and (ii) change a position thereof within the structure(s) to change the first angle. | 03-12-2015 |
| 20150031641 | METHODS AND COMPOSITIONS FOR THE DIAGNOSIS, PROGNOSIS AND TREATMENT OF ACUTE MYELOID LEUKEMIA - Gene mutations are associated with the progression of acute myeloid leukemia (AML). The invention relates to methods and systems for evaluating the progression of AML based on these gene mutations. The present invention also relates to methods and compositions for treating AML patients by modulating the expression or activity of certain genes involved in AML progression and/or their encoded proteins. The invention further relates to methods and compositions for determining the responsiveness of an AML patient to induction chemotherapy therapy. | 01-29-2015 |
| 20140365137 | SYSTEM, METHOD AND COMPUTER-ACCESSIBLE MEDIUM FOR QUANTIFYING FDG UPTAKE ON PET - The increasing use of molecular imaging probes as biomarkers in oncology can emphasize the need for robust and stable methods for quantifying tracer uptake on PET. A histogram-based system, method and computer-accessible procedure can be used to calculate a new tracer uptake metric and the background subtracted lesion activity. | 12-11-2014 |
| 20140308204 | FREE PSA ANTIBODIES AS DIAGNOSTICS, PROGNOSTICS AND THERAPEUTICS FOR PROSTATE CANCER - The present invention provides methods of monitoring and measuring tumor-associated free PSA (“fPSA”) with antibody polypeptides as an indication of androgen receptor signaling. In a particular embodiment, the methods may be used to assess the efficacy of anti-androgen and/or general anti-cancer treatments. The present invention also provides various methods and compositions relating to antibodies that are specific for tumor-associated or intratumoral fPSA. For example, the present invention provides compositions, including pharmaceutical compositions, comprising anti-fPSA antibodies, or fragments or characteristic portions thereof. The present invention further provides various therapeutic and/or diagnostic methods of using anti-fPSA antibodies and/or compositions. | 10-16-2014 |
| 20140296492 | HLA-RESTRICTED, PEPTIDE-SPECIFIC ANTIGEN BINDING PROTEINS - Antigen binding proteins with TCR-like paratopes, that is, with an antigen binding region specific for an HLA-A2 restricted peptide are disclosed. The antigen binding proteins encompass antibodies in a variety of forms, including full-length antibodies, substantially intact antibodies, Fab fragments, F(ab′)2 fragments, and single chain Fv fragments. Fusion proteins, such as scFv fusions with immunoglobulin or T-cell receptor domains, incorporating the specificity of the antigen binding region for each peptide are also contemplated by the invention. Furthermore, immunoconjugates may include antibodies to which is linked a radioisotope, fluorescent or other detectable marker, cytotoxin, or other molecule are also encompassed by the invention. Among other things, immunoconjugates can be used for delivery of an agent to elicit a therapeutic effect or to facilitate an immune effector function. | 10-02-2014 |
| 20140294841 | T CELL RECEPTOR-LIKE ANTIBODIES SPECIFIC FOR A WTI PEPTIDE PRESENTED BY HLA-A2 - The present invention provides antigen binding proteins that specifically bind to Wilms' tumor protein (WT1), including humanized, chimeric and fully human antibodies against WT1, antibody fragments, chimeric antigen receptors (CARs), fusion proteins, and conjugates thereof. The antigen binding proteins and antibodies bind to HLA-A0201-restricted WT1 peptide. Such antibodies, fragments, fusion proteins and conjugates thereof are useful for the treatment of WT1 associated cancers, including for example, breast cancer, ovarian cancer, prostate cancer, chronic myelocytic leukemia, multiple myeloma, acute lymphoblastic leukemia (ALL), acute myeloid/myelogenous leukemia (AML) and myelodysplastic syndrome (MDS). In more particular embodiments, the anti-WT1/A antibodies may comprise one or more framework region amino acid substitutions designed to improve protein stability, antibody binding and/or expression levels. | 10-02-2014 |
| 20140275174 | TREATMENT OF OVARIAN CANCER WITH 2-AMINO-4H-NAPHTHO[1,2-b]PYRAN-3-CARBONITRILES - Methods for inhibiting the growth of ovarian cancer cells or other serosal cancer cells are disclosed. The method involves exposing the cells to a 2-amino-4H-naphtho[1,2-b]pyran-3-carbonitrile of formula: | 09-18-2014 |
| 20140271677 | Newcastle Disease Viruses and Uses Thereof - Described herein are chimeric Newcastle disease viruses engineered to express an agonist of a co-stimulatory signal of an immune cell and compositions comprising such viruses. Also described herein are chimeric Newcastle disease viruses engineered to express an antagonist of an inhibitory signal of an immune cell and compositions comprising such viruses. The chimeric Newcastle disease viruses and compositions are useful in the treatment of cancer. In addition, described herein are methods for treating cancer comprising administering Newcastle disease viruses in combination with an agonist of a co-stimulatory signal of an immune and/or an antagonist of an inhibitory signal of an immune cell. | 09-18-2014 |
| 20140271644 | COMBINATION/ADJUVANT THERAPY FOR WT-1-POSITIVE DISEASE - In an attempt to improve primary disease responsiveness and/or to overcome resistant disease, the present disclosure provides a method for treating or inhibiting the proliferation of a WT-1-dependent cancer comprising providing to a subject in need thereof a therapeutically effective amount of a tyrosine kinase inhibitor along with an anti-WT-1/HLA antibody, that is, an antibody that specifically binds to a peptide of Wilms' tumor protein (WT-1) presented on the surface of the cancer cells in an HLA-restricted fashion. | 09-18-2014 |
| 20140257092 | INTERNATIONAL BODY CAVITY THERAPEUTIC APPLICATOR ARRANGEMENTS AND METHODS FOR USING THE SAME - An apparatus for providing at least one treatment to at least one tissue having a first structural arrangement configured to expand a first portion at a distal end of the apparatus, a second structural arrangement configured to expand a second portion at the distal end and at least one lumen associated with at least one of the first structural arrangement and/or the second structural arrangement. The first structural arrangement and/or the second structural arrangement can be configured to position the at least one lumen at a particular position with respect to the tissue. A tip is configured to aid in the insertion of the apparatus into the tissue(s). | 09-11-2014 |
| 20140255308 | 6-AMIDO DERIVATIVES OF 4, 5-a EPOXYMORPHINANS FOR THE TREATMENT OF PAIN - Compounds of formula: | 09-11-2014 |
| 20140248235 | Methods of Use for IL-22 Promoting Rejuvenation Of Thymic And Bone Marrow Function - The present invention provides methods and compositions for the use of IL-22 to promote thymic growth following thymic insult. In particularly preferred embodiments, the present invention provides methods of using therapeutic IL-22 compositions for treating patients with thymic atrophy and alterations in bone marrow derived white blood cells, including cancer patients undergoing chemotherapy, patients exposed to radiation (i.e. cancer therapy, nuclear disaster, terrorist attack, etc.), patients with HIV infections/AIDS, patients with organ transplantation, aging patients, and the like. In a further embodiment, therapeutic IL-22 compositions are contemplated as a prophylactic to boost immune response when additional T-cell function is needed, i.e. to boost immune response during vaccination. | 09-04-2014 |
| 20140234880 | METHODS OF DETECTION OF CANCER USING PEPTIDE PROFILES - The disclosed methods address the identification and monitoring of cancer in a subject using serum peptide profiles. Such profiles allow the detection of the differential presence of certain serum peptide markers in comparison with controls. The profiles can be determined employing mass spectrometry. | 08-21-2014 |
| 20140220346 | MODULAR POLYMER HYDROGEL NANOPARTICLES AND METHODS OF THEIR MANUFACTURE - In certain embodiments, a nano-sized vehicle (e.g., a nanogel comprising nanoparticles) is provided herein for drug delivery with tunable biodistribution, low toxicity, and degradability, and with demonstrated targeting to bone. The composition is useful, for example, in the treatment of bone disease, particularly bone metastases from cancers such as breast, prostate, or lung cancer. | 08-07-2014 |
| 20140205543 | METHOD FOR DIAGNOSING OR TREATING TUMORS USING SPHINGOMYELIN CONTAINING LIPOSOMES - The invention provides compositions and methods for diagnosing tumors and augmentic therapeutic intervention and measuring response to cell stress using sphingomyelin containing liposomes. The liposomes can include radiotracers, contrast agents, chromophores, dyes, enzyme substrates, therapeutic agents, chemotherapeutic agents or DNA segments. The indicators enable measurement of the extent of cellular release of Acid SMase at a localized site of cell stress. The nanoparticles have the capacity to locally release their contents, be it imaging (for diagnosis) or therapeutic agents (to augment therapy). | 07-24-2014 |
| 20140145568 | STORAGE ARRANGEMENT FOR MEDICALLY-RELATED TRANSPORT OR EVACUATION DEVICE(S) - An exemplary storage arrangement can be provided, which can include a first section and a second section. The first section can be moveable between a first configuration and a second configuration and can have at least one slot. The second section can be coupled to the first section and comprising at least one protrusion configured and dimensioned to mate with the slot(s) to facilitate movement of the first section. In the exemplary storage arrangement, the space formed by the first and second sections can receive a portable transportation arrangement, and at least one of the first section or the second section can be coupled to a configuration provided at or near a patient. Alternatively or in addition, the exemplary storage arrangement can include a locking mechanism which can be configured to secure at least one portion of the first section to the second section. | 05-29-2014 |
| 20140121126 | METHODS OF DETECTING AXL AND GAS6 IN CANCER PATIENTS - Described herein, inter alia, are compositions and methods for detecting levels of AXL and GAS6. | 05-01-2014 |
| 20140081218 | INTRAVENOUS DEVICE HAVING A MOVABLE ARRANGEMENT - An exemplary IV system can be provided which can include a drip chamber having a movable arrangement configured to mechanically move due to an impact thereof by at least one drop. The movable arrangement can include a spinning arrangement which is configured to spin due to the impact. The spinning arrangement can include a center portion having a plurality of protrusions, and can be mounted to the drip chamber using a mounting mechanism. | 03-20-2014 |
| 20140080838 | Methods for Treatment of Lymphomas with Mutations in Cell Cycle Genes - The present disclosure identifies a novel subtype of follicular lymphoma (FL) characterized by dysregulation of the cyclin/CDK/RB proliferative pathway. This subtype of FL is associated with increased malignancy and mortality, relative to FL which is not associated with cell cycle dysregulation. Accordingly, this disclosure presents novel methods to subtype FL and stratify patient risk by detection of biomarkers associated with RB inactivation. This disclosure further presents novel therapies for the treatment of FL subtyped by inactivation of RB. | 03-20-2014 |
| 20140079698 | ANTI-TUMOR ANTIBODY-TUMOR SUPPRESSOR FUSION PROTEIN COMPOSITIONS AND METHODS OF USE FOR THE TREATMENT OF CANCER - The present invention is directed to methods and compositions for treating cancer, including, hematologic malignancies, such as B-cell malignancies, with anti-tumor antibody-tumor suppressor fusion proteins in order to selectively restore tumor suppressor gene function to cancer cells in which such tumor suppressor gene function has been lost. The present invention is also directed to methods and compositions for diagnosing cancer and for predicting and assessing response to treatment. | 03-20-2014 |
| 20140044678 | CHIMERIC NEWCASTLE DISEASE VIRUSES AND USES THEREOF - Described herein are chimeric Newcastle disease viruses engineered to express a heterologous interferon antagonist and compositions comprising such viruses. The chimeric Newcastle disease viruses and compositions are useful in the treatment of cancer. | 02-13-2014 |
| 20140024809 | HLA-RESTRICTED, PEPTIDE-SPECIFIC ANTIGEN BINDING PROTEINS - Antigen binding proteins with TCR-like paratopes, that is, with an antigen binding region specific for an HLA-A2 restricted peptide are disclosed. The antigen binding proteins encompass antibodies in a variety of forms, including full-length antibodies, substantially intact antibodies, Fab fragments, F(ab′)2 fragments, and single chain Fv fragments. Fusion proteins, such as scFv fusions with immunoglobulin or T-cell receptor domains, incorporating the specificity of the antigen binding region for each peptide are also contemplated by the invention. Furthermore, immunoconjugates may include antibodies to which is linked a radioisotope, fluorescent or other detectable marker, cytotoxin, or other molecule are also encompassed by the invention. Among other things, immunoconjugates can be used for delivery of an agent to elicit a therapeutic effect or to facilitate an immune effector function. | 01-23-2014 |
| 20130324617 | CROWN-LIKE STRUCTURES AS A BIOMARKER FOR CANCER RISK AND CANCER PROGNOSIS - Chronic inflammation increases the risk of several epithelial malignancies. The present invention provides methods for determining cancer risk in a patient which comprises detecting the presence of crown-like structures (CLS), methods for treating cancer associated with CLS presence, methods for determining cancer risk in a patient by quantifying the number of CLS in a sample of adipose tissue of the patient, methods of determining prognosis of a patient with breast cancer or other cancers by detecting CLS, and screening methods for anti-cancer agents or agents that inhibit or reduce CLS formation or consequences thereof. | 12-05-2013 |
| 20130304432 | METHODS AND APPARATUS FOR PREDICTING PROTEIN STRUCTURE - The present invention relates to a method for predicting three-dimensional structure of a protein from its sequence. Three-dimensional structure may be determined by: (a) generating a multiple sequence alignment for a candidate protein having a known sequence; (b) identifying a covariance matrix between all pairs of sequence positions in the multiple sequence alignment; (c) inverting the covariance matrix and identifying predicted evolutionary constraints using a statistical model of the candidate protein; and (d) simulating folding of an extended chain structure of the candidate protein using the predicted constraints. | 11-14-2013 |
| 20130289060 | 6-AMIDO DERIVATIVES OF 4, 5-a EPOXYMORPHINANS FOR THE TREATMENT OF PAIN - Compounds of formula: | 10-31-2013 |
| 20130266980 | SYSTEM, DEVICE, METHOD AND COMPUTER ACCESSIBLE MEDIUM FOR IMAGING LARGE AREAS WITH MICROSCOPIC RESOLUTION - Exemplary systems, method and non-transitory computer-accessible medium can be provided for generating an image of at least one tissue that can be subdivided into a plurality of strips. Using such exemplary systems, method and computer-accessible medium, it is possible to scan, using an optical arrangement to generate first information, a first portion of the tissue(s) along a first one of the strips while the tissue(s) can be mechanically moved in a first direction. Move the one tissue(s), by a distance equal to or less than a width of the first portion, in a second direction approximately perpendicular to the first direction. Use the optical arrangement to generate second information, a second portion of the tissue(s) along a second one of the strips while the tissue(s) can be mechanically moved in a third direction, which can be approximately opposite to the first direction. Then the image can be generated based on the first information and the second information. | 10-10-2013 |
| 20130183674 | METHOD OF NOCICEPTOR DIFFERENTIATION OF HUMAN EMBRYONIC STEM CELLS AND USES THEREOF - The present invention relates to the field of stem cell biology, in particular the linage specific differentiation of pluripotent or multipotent stem cells, which can include, but is not limited to, human embryonic stem cells (hESC), human induced pluripotent stem cells (hiPSC), somatic stem cells, cancer stem cells, or any other cell capable of lineage specific differentiation. Specifically described are methods to direct the lineage specific differentiation of hESC and/or hiPSC to nociceptors (i.e. nociceptor cells) using novel culture conditions. The nociceptors made using the methods of the present invention are further contemplated for various uses including, but limited to, use in in vitro drug discovery assays, pain research, and as a therapeutic to reverse disease of, or damage to, the peripheral nervous system (PNS). Further, compositions and methods are provided for producing melanocytes from human pluripotent stem cells for use in disease modeling. | 07-18-2013 |
| 20130171152 | ANTIBODIES TO MUC16 AND METHODS OF USE THEREOF - The invention provides antibodies, and antigen-binding fragments thereof, that specifically bind to a polypeptide, or antigenic portion thereof, wherein the polypeptide is selected from a) MUC16 ectodomain polypeptide, b) MUC16 cytoplasmic domain polypeptide, and c) MUC16 extracellular domain polypeptide that contains a cysteine loop polypeptide. The invention's antibodies and compositions containing them are useful in diagnostic and therapeutic applications for diseases in which MUC16 is overexpressed, such as cancer. | 07-04-2013 |
| 20130121960 | CONSTITUTIVE EXPRESSION OF COSTIMULATORY LIGANDS ON ADOPTIVELY TRANSFERRED T LYMPHOCYTES - The present invention provides immunoresponsive cells, including T cells, cytotoxic T cells, regulatory T cells, and Natural Killer (NK) cells, expressing at least one of an antigen-recognizing receptor and a co-stimulatory ligand and methods of use therefore for the treatment of neoplasia and other pathologies where an increase in an antigen-specific immune response is desired. | 05-16-2013 |
| 20130078319 | DETECTION OF OVARIAN CANCER - Among other things, the present disclosure provides a method including the steps of: obtaining a uterine sample; and detecting and/or characterizing in the uterine sample an ovarian cancer biomarker (e.g., CA125). | 03-28-2013 |
| 20130072844 | USE OF ENTRAINED NEUTROPHILS TO TREAT METASTATIC AND MICROMETASTATIC DISEASE IN AT RISK PATIENTS - The present invention relates generally to compositions and methods for treating cancer patients with a poor prognosis, and to therapeutic modalities for improving prognosis by combating metastasis and abrogating chemoresistance in cancer cells. In particular, the invention relates to the role of white blood cells, i.e. neutrophils and neutrophil-like cells, in preventing the spread of cancer from a primary tumor to secondary locations in the body. The invention provides methods for reducing or delaying the spread of metastatic cancer cells in a patient at risk for metastatic tumor development, at risk for metastatic relapse, i.e. prophylactic methods, and treating patients suffering from metastatic tumors. | 03-21-2013 |
| 20120302828 | APPARATUS, SYSTEM AND METHOD FOR PROVIDING LASER STEERING AND FOCUSING FOR INCISION, EXCISION AND ABLATION OF TISSUE IN MINIMALLY-INVASIVE SURGERY - Exemplary embodiments of apparatus, system, computer-accessible medium, procedure and method are provided which can be used for providing laser steering and focusing for, e.g., incision, excision and/or ablation of tissue in minimally-invasive surgery. For example, the exemplary apparatus can include at least one optical element which can be configured to refract and/or diffract light provided in a structure which can be configured to be inserted into a body, where at least one of the optical element(s) is structured to receive the light at a first angle and generate a refracted and/or diffracted light at a second angle which can be different from the first angle relative to an optical axis. For example, an actuating arrangement can be provided, which can be configured to control the optical element(s), can be provided and situated at least partially within the at least one structure. | 11-29-2012 |
| 20120264620 | METHODS FOR DIAGNOSIS AND TREATMENT OF ENDOMETRIAL CANCER - The present invention discloses methods of using endothelial membrane protein 2 (EMP2) as a biomarker for stratification of endometrial premalignancy, diagnosing, staging and imaging of endometrial neoplasia. Further, methods for identifying pharmaceutical/therapeutic modalities are described, including compositions which modulate glycolipid-enriched lipid raft microdomains (GEMs). | 10-18-2012 |
| 20120252818 | HEAT SHOCK PROTEIN BINDING COMPOUNDS, COMPOSITIONS, AND METHODS FOR MAKING AND USING SAME - The present subject matter relates to a compound represented by the general formula (I) or (I′) or a pharmacologically acceptable salt thereof; pharmaceutical compositions containing at least one of these compounds; methods of making at least one of these compounds; methods of using at least one of these compounds for treating and/or preventing various cancers and/or proliferation disorders; methods of using at least one of these compounds for monitoring the effectiveness of an anticancer therapy against various cancers. In one embodiment, the subject matter relates to compounds that bind with a level of specificity to heat shock protein 70 (Hsp70). In another embodiment, the subject matter relates to compounds that bind with a level of specificity to inhibit both heat shock protein 70 (Hsp70) and heat shock cognate protein 70 (Hsc70). | 10-04-2012 |
| 20120251556 | Combination Immunotherapy for the Treatment of Cancer - Agonists to ICOS in combination with a blocking agent to a T cell inhibitory receptor (e.g., CTLA-4, PD-I, etc.) are demonstrated herein to be useful for the treatment of tumors. | 10-04-2012 |
| 20120077201 | Methods and Compositions for Detecting a Drug Resistant EGFR Mutant - Development of acquired resistance to the therapeutic effects of an epidermal growth factor (EGFR) tyrosine kinase inhibitor in a patient that is suffering from a cancer is predicted by:
| 03-29-2012 |
| 20110257027 | GAMMA-SECRETASE SUBSTRATE AND METHODS OF USE - Polypeptide substrates based on modifications or fragments of the various APP isoforms, assay methods based on the use of these substrates, and screening methods directed toward identifying inhibitors of γ-secretase activity. The assay methods and the screening methods are adapted for use in high throughput multi-well plate assay apparatuses. In many embodiments the substrate polypeptides are labeled for ease of detection, and/or may bind specific ligands that themselves are labeled. Generally the labels promote high specificity as well as high sensitivity of detection. These features render the assay and screening methods that employ the labeled substrates especially suited for use in high throughput assay formats. This disclosure further identifies small polypeptides based on a subsequence motif of Aβ that are shown herein to be potent inhibitors of the activity of γ-secretase. | 10-20-2011 |
| 20110237549 | MODULATORS OF RNA RIBOSWITCHES - Provided is a computer model generated from a data array, computer readable storage media encoded with the model, and computers comprising the model, wherein the model is derived from atomic structure coordinates of a FMN riboswitch or a lysine riboswitch. Further provided is a pharmacophore having a spatial arrangement of atoms defined by the binding pocket identified in the model, along with a compound defined by the pharmacophore. Also further provided are methods for rational drug design based on the atomic structure data, and compounds identified by the rational drug design process. | 09-29-2011 |
| 20110143954 | GAMMA-SECRETASE SUBSTRATE AND METHODS OF USE - Polypeptide substrates based on modifications or fragments of the various APP isoforms, assay methods based on the use of these substrates, and screening methods directed toward identifying inhibitors of γ-secretase activity. The assay methods and the screening methods are adapted for use in high throughput multi-well plate assay apparatuses. In many embodiments the substrate polypeptides are labeled for ease of detection, and/or may bind specific ligands that themselves are labeled. Generally the labels promote high specificity as well as high sensitivity of detection. These features render the assay and screening methods that employ the labeled substrates especially suited for use in high throughput assay formats. This disclosure further identifies small polypeptides based on a subsequence motif of Aβ that are shown herein to be potent inhibitors of the activity of γ-secretase. | 06-16-2011 |
| 20110091573 | PROCESS FOR PRODUCING ARSENIC TRIOXIDE FORMULATIONS AND METHODS FOR TREATING CANCER USING ARSENIC TRIOXIDE OR MELARSOPROL - The invention relates to the use of arsenic compounds to treat a variety of leukemia, lymphoma and solid tumors. Further, the arsenic compounds may be used in combination with other therapeutic agents, such as a retinoid. The invention also provides a process for producing arsenic trioxide formulations. | 04-21-2011 |
| 20110052554 | METHODS FOR OFF-THE- SHELF TUMOR IMMUNOTHERAPY USING ALLOGENEIC T-CELL PRECURSORS - The inventive subject matter relates to methods for treating a T-cell deficiency in a subject in need thereof, comprising administering to said subject a T-cell precursor isolated from an allogeneic donor, provided that said allogeneic donor is not MHC-matched to said subject. The inventive methods can be further enhanced by genetic engineering for targeted immunotherapy. | 03-03-2011 |
| 20100285988 | Gamma-Secretase Substrates And Methods Of Use - Polypeptide substrates based on modifications or fragments of the various APP isoforms, assay methods based on the use of these substrates, and screening methods directed toward identifying inhibitors of γ-secretase activity. The assay methods and the screening methods are adapted for use in high throughput multi-well plate assay apparatuses. In many embodiments the substrate polypeptides are labeled for ease of detection, and/or may bind specific ligands that themselves are labeled. Generally the labels promote high specificity as well as high sensitivity of detection. These features render the assay and screening methods that employ the labeled substrates especially suited for use in high throughput assay formats. This disclosure further identifies small polypeptides based on a subsequence motif of Aβ that are shown herein to be potent inhibitors of the activity of γ-secretase. | 11-11-2010 |
| 20100178276 | CONSTITUTIVE EXPRESSION OF COSTIMULATORY LIGANDS ON ADOPTIVELY TRANSFERRED T LYMPHOCYTES - The present invention provides immunoresponsive cells, including T cells, cytotoxic T cells, regulatory T cells, and Natural Killer (NK) cells, expressing at least one of an antigen-recognizing receptor and a co-stimulatory ligand and methods of use therefore for the treatment of neoplasia and other pathologies where an increase in an antigen-specific immune response is desired. | 07-15-2010 |
| 20100173285 | Methods and Compositions for Detecting a Drug Resistant Egfr Mutant - Polymerase chain reaction primers and methods directed to detecting the EGFR mutant C→T at the position corresponding to base 2369 of EGFR cDNA. The invention provides a PCR primer that hybridizes under suitable PCR conditions to a polynucleotide sequence 5′ in each respective strand to a mutation of an EGFR gene that encodes a substitution of threonine by methionine at position 790 of the EGFR polypeptide. The invention also provides a PCR primer hybridizes to a sequence that includes a mutant T at the position corresponding to base 2369 of EGFR cDNA but not to a second EGFR polynucleotide containing a wild type C. The invention provides several methods and kits for detecting a mutant epidermal growth factor receptor (EGFR) gene in a sample comprising probing the sample with a means for selectively detecting a nucleotide sequence comprising a mutant T at the position corresponding to base 2369 of EGFR cDNA, and identifying that the base at said position is T. These methods and kits are also useful to predict resistance to the therapeutic effects of gefitinib or erlotinib in a subject suffering from or suspected of having a cancer. | 07-08-2010 |
| 20100010064 | Cancer treatment by combined inhibition of proteasome and telomerase activities - A method and kit for inhibiting the proliferation of cancer cells are disclosed, based on a combination of a proteasome inhibitor and a telomerase inhibitor. When used in cancer therapy, the two compounds in combination enhance the anti-cancer treatment efficacy obtained with the proteasome inhibitor alone or the telomerase inhibitor alone. Preferably, efficacy is supraadditive or synergistic in nature relative to the combined effects of the individual agents, with minimal exacerbation of side effects. | 01-14-2010 |
| 20090274671 | VECTOR ENCODING HUMAN GLOBIN GENE AND USE THEREOF IN TREATMENT OF HEMOGLOBINOPATHIES - Recombinant lentiviral vectors having a region encoding a functional β-globin gene; and large portions of the β-globin locus control regions which include DNase I hypersensitive sites HS2, HS3 and HS4 provides expression of β-globin when introduced into a mammal, for example a human, in vivo. Optionally, the vector further includes a region encoding a dihydrofolate reductase. The vector may be used in treatment of hemoglobinopathies, including β-thalessemia and sickle-cell disease. For example, hematopoietic progenitor or stem cells may be transformed ex vivo and then restored to the patient. Selection processes may be used to increase the percentage of transformed cells in the returned population. For example, a selection marker which makes transformed cells more drug resistant than untransformed cells allows selection by treatment of the cells with the corresponding drug. | 11-05-2009 |
| 20090156534 | GLOBIN LENTIVIRAL VECTORS FOR TREATMENT OF DISEASE - The invention provides compositions and methods for the treatment or prevention of disease, including, for example, β-thalassemia, anemias (e.g., sickle cell anemia) and other hemoglobinopathologies. | 06-18-2009 |
| 20080317763 | Regulation of Metalloprotease Cleavage of Cell Surface Proteins - Elucidation of the crystal structure of an ADAM10 substrate-recognition and proteinase-positioning module comprising the protein cysteine-rich and disintegrin domains, and detailed functional analysis revealed that an acidic pocket within the cysteine-rich domain forms a substrate-recognition site. The binding of this pocket to receptor/ligand complexes facilitates effective ligand cleavage, which is prevented when critical residues within the pocket are changed. This provides use of the surface pocket within the extracellular domain of ADAM10, and the corresponding structure in related proteases such as ADAM17, as a target for structure-based computational and high-throughput screens for small-molecule substrate-specific inhibitors or monoclonal antibodies that inhibit ADAM protease cleavage of ephrins and other ADAM10 or ADAM17 substrates. These inhibitors will be useful in therapeutic intervention of tumour development, invasion and metastasis and other diseases which involve the activity of the ADAM10 and ADAM17 proteases, such as inflammation, cardio-vascular disease, arthritis and other auto-immune diseases. | 12-25-2008 |
